roflumilast
arcutis biotherapeutics,astrazeneca
['integument-1', 'atopic dermatitis ', 'integument-2', 'derm', 'arcutis']
#news: today, we shared new data from the integument-1 and integument-2 phase 3 #clinicaltrials evaluating our steroid-free, topical cream in adults and children with mild to moderate #atopicdermatitis. full results will be presented at #aad2023. 
Bioscience, applied to the skin. | Arcutis is addressing the innovation gap in medical #dermatology drug development. $ARQT #DermTwitter #Immunodermatology